David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study (French Language Version)

Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses in French this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1).

Lymphoma

Andrew J. Davies, MRCP, PhD

Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results

Andrew J. Davies, MRCP, PhD, of the Cancer Research UK Centre, University of Southampton, discusses a study of targeted treatment for diffuse large B-cell lymphoma based on real-time gene-expression profiling (Abstract 812).

Lymphoma

Nathan Hale Fowler, MD

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular lymphoma (Abstract 470).

Leukemia

Lymphoma

Sagar Lonial, MD, and Alessandra Tedeschi, MD

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Sagar Lonial, MD, of the Emory University School of Medicine, and Alessandra Tedeschi, MD, of the Azienda Ospedaliera Niguarda Cà Granda, discuss this international study of ibrutinib vs chlorambucil in patients 65 years and older with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma (Abstract 495).

Lymphoma

Laurie H. Sehn, MD, MPH

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).

Apr

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study (French Language Version)

Andrew J. Davies, MRCP, PhD, on DLBCL: The Remodl-B Clinical Trial Results

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Sagar Lonial, MD, and Alessandra Tedeschi, MD, on CLL/SLL: Results From the RESONATE-2 Trial

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs

AI Model May Help Predict Treatment Responses Select Most Effective Cancer Therapies in Patients With Cancer

In-Hospital Mortality Among Patients With COVID-19 Infection, With or Without Cancer

Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved

Potential Protective Effects of Aspirin Against Colorectal Cancer